With the resurgence of the cannabis space so far in place in 2019, Aleafia Health Inc (OTCMKTS:ALEAF) has been a clear standout performer. One of the themes in place defining the momentum in the space has been greater formal establishment of the industry of cannabis as a viable enterprise, including from an intellectual perspective. As a case in point, the company just announced that it has appointed Dr. Graham Merry, as the Company’s first Product Data Science Fellow.
According to the release, “Leveraging the Company’s proprietary 10 million point medical cannabis patient dataset, Dr. Merry will lead Aleafia Health’s ongoing medical cannabis research. These efforts will be aimed at developing evidence-based, proprietary treatment methods and products for chronic illnesses including pain, insomnia, anxiety and eating disorders.”
Aleafia Health Inc (OTCMKTS:ALEAF) bills itself as a company that owns and operates a healthcare clinic that provides medical cannabis therapy to achieve optimum recovery and minimize illness and injury’s cumulative effects. The company provides medical cannabis therapy, pain management, physiotherapy, chiropractor, osteopathy, registered massage therapy, laser therapy, orthotics, and custom braces and compression socks. It provides consulting and support services for managing cannabis-sensitive cases.
The company assists rehabilitation professionals, case managers, social workers, life care planners, psychologists, family physicians, physiotherapists, litigators, and third-party insurance companies. Aleafia Inc. is based in Concord, Canada.
According to company materials, “Aleafia is a leading, vertically integrated medical cannabis company with a unique focus on delivering quality patient care from “seed” to “sale.” Aleafia is uniquely positioned with a singular focus on the medical cannabis market. The company operates the largest brick and mortar medicinal cannabis clinic network in Canada under the Canabo Medical Clinic brand, which is staffed by licensed, practicing physicians. Aleafia has obtained over 50,000 unique patients and maintains the largest medical cannabis patient data set in Canada. Aleafia’s state of the art production facilities will allow for the production of high-quality strains at low cost. Aleafia’s production will focus on securing the highest-quality medicinal product for its growing patient base.”
Find out when $ALEAF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, ALEAF just announced that it has appointed Dr. Graham Merry, as the Company’s first Product Data Science Fellow. In all, we’ve witnessed 90% tacked on to share pricing for the company in the past month.
In addition, the listing has seen interest climb, with an increase in recent trading volume of approaching 130% above its longer-run average levels.
“Aleafia Health continues to accelerate our purpose of helping people live better lives through a unique, scalable cannabis consumer experience. We will enable patients to navigate seamlessly through, cannabis education, illness specific questionnaires, medical cannabis script product purchasing, order subscription management and treatment/titration monitoring,” said Aleafia Health CEO Geoffrey Benic. “We look forward to Dr. Merry leading our research efforts and team and making significant contributions to evidence based medicine.”
Earning a current market cap value of $308.03M, ALEAF has a significant war chest ($22.8M) of cash on the books, which is balanced by about $1.8M in total current liabilities. ALEAF is pulling in trailing 12-month revenues of $4.2M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 79.5%. We will update the story again soon as developments transpire. Sign-up for continuing coverage on shares of $ALEAF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $ALEAF, either long or short, and we have not been compensated for this article.